These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32312344)

  • 1. The network structure of core depressive symptom-domains in major depressive disorder following antidepressant treatment: a randomized clinical trial.
    Berlim MT; Richard-Devantoy S; Dos Santos NR; Turecki G
    Psychol Med; 2021 Oct; 51(14):2399-2413. PubMed ID: 32312344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
    Chakrabarty T; McInerney SJ; Torres IJ; Frey BN; Milev RV; Müller DJ; Rotzinger S; Kennedy SH; Lam RW;
    CNS Drugs; 2021 Mar; 35(3):291-304. PubMed ID: 33683582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of desvenlafaxine on neurocognitive and work functioning in employed outpatients with major depressive disorder.
    Lam RW; Iverson GL; Evans VC; Yatham LN; Stewart K; Tam EM; Axler A; Woo C
    J Affect Disord; 2016 Oct; 203():55-61. PubMed ID: 27280963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysis.
    Lam RW; Wajsbrot DB; Meier E; Pappadopulos E; Mackell JA; Boucher M
    J Psychopharmacol; 2017 Sep; 31(9):1204-1214. PubMed ID: 28718346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of fatigue and energy on work functioning and impairment in patients with major depressive disorder treated with desvenlafaxine.
    Sarfati D; Evans VC; Tam EM; Woo C; Iverson GL; Yatham LN; Lam RW
    Int Clin Psychopharmacol; 2017 Nov; 32(6):343-349. PubMed ID: 28763344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder.
    Carrasco JL; Kornstein SG; McIntyre RS; Fayyad R; Prieto R; Salas M; Mackell J; Boucher M
    Int Clin Psychopharmacol; 2016 May; 31(3):134-46. PubMed ID: 26895080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of desvenlafaxine versus placebo on MDD symptom clusters: A pooled analysis.
    Katzman MA; Wang X; Wajsbrot DB; Boucher M
    J Psychopharmacol; 2020 Mar; 34(3):280-292. PubMed ID: 31913085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials: Toward Personalized Treatment for Depression.
    Zilcha-Mano S; Wang X; Wajsbrot DB; Boucher M; Fine SA; Rutherford BR
    J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):579-584. PubMed ID: 34183490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placebo.
    Kornstein SG; Fava M; Jiang Q; Tourian KA
    Psychopharmacol Bull; 2009; 42(3):21-35. PubMed ID: 19752839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy.
    Akiskal HS; Benazzi F; Perugi G; Rihmer Z
    J Affect Disord; 2005 Apr; 85(3):245-58. PubMed ID: 15780694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of desvenlafaxine on cognitive functioning in employed outpatients with major depressive disorder: a substudy of a randomized, double-blind, placebo-controlled trial.
    Reddy S; Fayyad R; Edgar CJ; Guico-Pabia CJ; Wesnes K
    J Psychopharmacol; 2016 Jun; 30(6):559-67. PubMed ID: 27009044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of functional outcome in patients with major depression and bipolar disorder: A dynamic network approach to identify distinct patterns of interacting symptoms.
    Platania GA; Savia Guerrera C; Sarti P; Varrasi S; Pirrone C; Popovic D; Ventimiglia A; De Vivo S; Cantarella RA; Tascedda F; Drago F; Di Nuovo S; Colliva C; Caraci F; Castellano S; Blom JMC
    PLoS One; 2023; 18(2):e0276822. PubMed ID: 36791083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between plasma serotonin and kynurenine pathway metabolite levels and the treatment response to escitalopram and desvenlafaxine.
    Sun Y; Drevets W; Turecki G; Li QS
    Brain Behav Immun; 2020 Jul; 87():404-412. PubMed ID: 31978524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between work functioning and self-reported cognitive complaints in patients with major depressive disorder treated with desvenlafaxine.
    Alonso-Prieto E; Rubino C; Lucey M; Evans VC; Tam EM; Woo C; Iverson GL; Chakrabarty T; Yatham LN; Lam RW
    Psychiatry Res; 2019 Feb; 272():144-148. PubMed ID: 30583256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Symptom Network Structure With the Course of [corrected] Depression.
    van Borkulo C; Boschloo L; Borsboom D; Penninx BW; Waldorp LJ; Schoevers RA
    JAMA Psychiatry; 2015 Dec; 72(12):1219-26. PubMed ID: 26561400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.
    Zisook S; Lesser IM; Lebowitz B; Rush AJ; Kallenberg G; Wisniewski SR; Nierenberg AA; Fava M; Luther JF; Morris DW; Trivedi MH
    J Clin Psychiatry; 2011 Oct; 72(10):1322-32. PubMed ID: 22075098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.
    Kornstein SG; Clayton AH; Bao W; Guico-Pabia CJ
    J Womens Health (Larchmt); 2015 Apr; 24(4):281-90. PubMed ID: 25860107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Network analysis of the Quick Inventory of Depressive Symptomatology: Reanalysis of the STAR*D clinical trial.
    Madhoo M; Levine SZ
    Eur Neuropsychopharmacol; 2016 Nov; 26(11):1768-1774. PubMed ID: 27707535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: a randomized, open-label controlled trial.
    Maity N; Ghosal MK; Gupta A; Sil A; Chakraborty S; Chatterjee S
    Indian J Pharmacol; 2014; 46(4):433-7. PubMed ID: 25097285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.